Compare Godaddy Inc (GDDY) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Godaddy Inc vs Merck & Co., Inc. — how do they compare? Godaddy Inc trades at $104.74 (market cap $13.07B), while Merck & Co., Inc. trades at $146.23 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 26.9× Godaddy Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Godaddy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Godaddy Inc for 64 Days and Merck & Co., Inc. for 98 Days on average.
| GDDY | MRK | |
|---|---|---|
Market Cap | $13.07B | $351.28B |
Volume | 1,831,274 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $135.18 | $156.43 |
52-Week Low | $75.07 | $82.49 |
Typical Hold Time | 64 Days | 98 Days |
Enterprise Value | $15.75B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GoDaddy (GDDY) trades at $104.7, up 7.7% in the last 24 hours, with a bullish technical signal from moving averages. The company reported revenue of $4.95B in 2025 and net income of $875M, with consistent earnings beats in recent quarters. However, the stock faces headwinds from a securities class action lawsuit alleging misrepresentations about domain contract terms, with a lead plaintiff deadline of October 20, 2026.
The outlook is mixed: strong profitability and earnings momentum support upside, but legal risks and a consensus price target of $96.20 suggest caution. Investors should weigh robust fundamentals against potential litigation impacts and market sentiment shifts.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Godaddy Inc
GoDaddy is a provider of domain registration and aftermarket services, website hosting, security, design, and business productivity tools, commerce solutions, and domain registry services. The company primarily targets micro- to small businesses, website design professionals, registrar peers, and domain investors. Since acquiring payment processing platform Poynt in 2021, the company has expanded into omnicommerce solutions, including offering an online payment gateway and offline point-of-sale devices.
Read more on GDDY →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
